Synthetic Peptide for Neuropharmacology Research

Technical Overview

PE-22-28 is a heptapeptide fragment corresponding to the C-terminal 22-28 region of spadin, the propeptide released during sortilin maturation. It selectively inhibits the TREK-1 (KCNK2) two-pore-domain potassium channel, modulating neuronal excitability in preparations from cortex, hippocampus, and dorsal raphe.

Researchers employ PE-22-28 to probe TREK-1 contributions to fast-onset antidepressant signaling, neurogenesis, and serotonergic activity in rodent brain-slice and primary-culture models. Its relative ease of synthesis compared to full-length spadin makes it the preferred tool compound for TREK-1 antagonism studies.

This compound is synthesized using established solid-phase peptide synthesis methods and purified through reversed-phase HPLC to achieve analytical purity suitable for laboratory assays, binding studies, and analytical applications. The lyophilized material is supplied for reconstitution per established laboratory protocols and is intended as a reference material in controlled research environments.

Specifications

Compound Name: PE-22-28
Strength: 10mg
Purity: ≥ 99% (HPLC Verified)
Appearance: Lyophilized Peptide Powder
Format: Research Compound
Reconstitution: Suitable for laboratory assay preparation.

Notice

Provided as a reference material for scientific investigation only.